
|Articles|April 15, 2020
VIDEO SPECIAL: The Cardiac Dangers of Hydroxychloroquine and Azithromycin
Dr. Mariell Jessup, Chief Science and Medical Officer at the AHA discusses the cardiac dangers of combining hydroxychloroquine and azithromycin to treat coronavirus patients with underlying heart disease, the controversy surrounding putting medical students and trainees on the frontlines of COVID-19 too soon, and the changing roles of telemedicine.
Advertisement
Dr. Mariell Jessup, Chief Science and Medical Officer at the AHA discusses the cardiac dangers of combining hydroxychloroquine and azithromycin to treat coronavirus patients with underlying heart disease, the controversy surrounding putting medical students and trainees on the frontlines of COVID-19 too soon, and the changing roles of telemedicine.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
What Comes Next for Berobenatide? VESPER-3 and Phase 3 Expectations, With John Buse, MD, PhD
3
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
4
Ketone Monitoring in Diabetes: Making The Case For When and How to Test
5


























































